

Max Senna Mano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/318805/publications.pdf>

Version: 2024-02-01

35
papers

2,067
citations

758635

12
h-index

433756

31
g-index

38
all docs

38
docs citations

38
times ranked

2996
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Implementing multidisciplinary tumor boards in oncology: a narrative review. <i>Future Oncology</i> , 2022, 18, 375-384. | 1.1 | 12 |
| 2 | Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil. <i>Oncologist</i> , 2022, . . | 1.9 | 1 |
| 3 | Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 28-37. | 1.8 | 10 |
| 4 | Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: A GBECAM multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18822-e18822. | 0.8 | 0 |
| 5 | Interfaces between medical practice and trading: lessons from the markets. <i>Postgraduate Medical Journal</i> , 2021, 97, 411-412. | 0.9 | 0 |
| 6 | Is Independent Clinical Research Possible in Low- and Middle-Income Countries? A Roadmap to Address Persistent and New Barriers and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 221-230. | 1.8 | 3 |
| 7 | Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 58. | 1.8 | 1 |
| 8 | Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?. <i>Lancet Oncology</i> , The, 2021, 22, 1365-1366. | 5.1 | 2 |
| 9 | Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. <i>Clinics</i> , 2021, 76, e3146. | 0.6 | 2 |
| 10 | Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. <i>Future Oncology</i> , 2020, 16, 2595-2609. | 1.1 | 3 |
| 11 | The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 749-757. | 1.1 | 31 |
| 12 | Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptorâ€“Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. <i>Breast</i> , 2020, 54, 331-334. | 0.9 | 2 |
| 13 | Impact of preoperative magnetic resonance imaging (MRI) on conservative surgery (CSur) among curable breast cancer (BC) patients treated in a specialized center in Latin America.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12595-e12595. | 0.8 | 0 |
| 14 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 617-628. | 13.9 | 1,610 |
| 15 | Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 513-513. | 0.8 | 3 |
| 16 | Mammary adenectomy followed by immediate reconstruction for treatment of patients with early-infiltrating breast carcinoma: a cohort study. <i>Sao Paulo Medical Journal</i> , 2019, 137, 336-342. | 0.4 | 2 |
| 17 | Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. <i>Breast</i> , 2018, 38, 39-44. | 0.9 | 23 |
| 18 | Leadership Competencies in Medical Education: The Importance of Cross-Cultural Validation. <i>Journal of Global Oncology</i> , 2018, 4, 1-4. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. <i>Biomarker Research</i> , 2018, 6, 20. | 2.8 | 7 |
| 20 | Reply to: Mastectomy skin flap thickness. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1119-1120. | 0.5 | 1 |
| 21 | Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2036-2043. | 0.5 | 16 |
| 22 | Do socioeconomic status and comorbidity affect survival in women with breast cancer living in the city of São Paulo, Brazil?. <i>Journal of Clinical Oncology</i> , 2017, 35, e18150-e18150. | 0.8 | 0 |
| 23 | Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. <i>Breast Cancer</i> , 2016, 23, 261-265. | 1.3 | 2 |
| 24 | Rare tumors research in emerging countries. <i>Rare Tumors</i> , 2010, 2, 142-143. | 0.3 | 6 |
| 25 | Building research capacity and clinical trials in developing countries. <i>Lancet Oncology</i> , The, 2010, 11, 712-713. | 5.1 | 10 |
| 26 | Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2008, 278, 457-462. | 0.8 | 14 |
| 27 | Colon Cancer: Update on Adjuvant Therapy. <i>Clinical Colorectal Cancer</i> , 2008, 7, 178-183. | 1.0 | 35 |
| 28 | Novel cytotoxic drugs: Old challenges, new solutions. <i>Cancer Treatment Reviews</i> , 2008, 34, 81-91. | 3.4 | 83 |
| 29 | The 17q12-q21 amplicon: Her2 and topoisomerase-III± and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77. | 3.4 | 69 |
| 30 | Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?. <i>European Journal of Cancer</i> , 2006, 42, 2675-2677. | 1.3 | 22 |
| 31 | Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. <i>Sao Paulo Medical Journal</i> , 2006, 124, 343-345. | 0.4 | 11 |
| 32 | Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. <i>Breast</i> , 2006, 15, 117-118. | 0.9 | 45 |
| 33 | Management of breast cancer in patients prenatally exposed to diethylstilbestrol: are we prepared?. <i>Breast</i> , 2005, 14, 408-410. | 0.9 | 2 |
| 34 | Liver metastases from breast cancer: management of patients with significant liver dysfunction. <i>Cancer Treatment Reviews</i> , 2005, 31, 35-48. | 3.4 | 20 |
| 35 | Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?. <i>Cancer Treatment Reviews</i> , 2005, 31, 69-78. | 3.4 | 2 |